目的 觀察去感熱口服液聯(lián)合利巴韋林治療急性上呼吸道感染的臨床療效。方法 選取宣漢縣人民醫(yī)院2015年1月-2015年12月收治的急性上呼吸道感染患者106例，隨機(jī)分為對(duì)照組和治療組，每組各53例。對(duì)照組靜脈滴注利巴韋林注射液，0.5 g加入到生理鹽水250 mL，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服去感熱口服液，10 mL/次，3次/d。兩組均連續(xù)治療7 d。觀察兩組患者臨床療效、臨床癥狀體征改善情況，對(duì)比兩組患者治療前后白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）指標(biāo)水平。結(jié)果 治療后，對(duì)照組的總有效率為73.58%，顯著低于治療組的92.45%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組退熱時(shí)間、咽痛消失時(shí)間、止咳時(shí)間及咽部充血消失時(shí)間均明顯短于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者IL-6和TNF-α指標(biāo)水平均顯著降低，同組差異比較具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組兩個(gè)指標(biāo)改善情況優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 去感熱口服液聯(lián)合利巴韋林治療急性上呼吸道感染療效確切，顯著改善癥狀體征和炎性指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical curative effect of Quganre Oral Liquid combined with ribavirin in treatment of acute upper respiratory tract infection. Methods Patients (106 cases) with acute upper respiratory tract infection in Xuanhan County People's Hospital from January 2015 to December 2015 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were iv administered with Ribavirin Injection, 0.5 g added into normal saline 250 mL, once daily. Patients in the treatment group were po administered with Quganre Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy, clinical symptoms and signs were evaluated, and IL-6 and TNF-α level in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 73.58%, which was significantly lower than 92.45% in the treatment group, and there was difference between two groups (P<0.05). After treatment, pyretolysis time, disappearing time of pharyngalgia, cough, and pharyngeal hyperemia in treatment group were significantly shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, IL-6 and TNF-α levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the two indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Quganre Oral Liquid combined with ribavirin has clinical effect in treatment of acute upper respiratory tract infection, can significantly improve symptoms and signs,and inflammatory indexes, which has a certain clinical application value.